It made the decision about the Opdivo and Yervoy combination after assessing the data available
Showing 25 of 5026
Prior to joining Motif Bio, Dickey was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company
“Summit has two strong scientific programmes with the potential to significantly advance the current standard of care in their respective disease areas," said new COO Dr David Roblin.
Sales reached a new high of $2.2 million in the period, it said, as it revealed an overall 2016 revenue of $8.2 million - a 28% increase on the previous year.
The drug product would be targeted at women with orgasm and arousal difficulties
Living Cell Technologies’ (ASX:LCT) patent application related to choroid plexus cells has been published by the U.S. patent office.
US officials said Shire Pharmaceuticals will pay $350m to settle allegations that it used “kickbacks and other unlawful methods” to induce doctors to use a product aimed at treating foot ulcers
Pressure Biosciences' President and CEO Richard T. Schumacher will present a corporate overview at the 9th Annual Biotech Showcase at 1700 PST later today
The Canadian group announced the deal to acquire Cincinatti-based 40Js on 4 January
Clinigen and Cumberland formed their alliance last year and have already launched one drug, Ethyol
M Pharma has signed a letter of intent to buy 100% of Cincinnati-based healthcare group 40J’s LLC
VolitionRx announced on Wednesday that it will present at the 9th annual Biotech Showcase Conference being held from January 9-11 in San Francisco, CA
M Pharmaceutical Inc shares jumped more than 12% on Thursday as the company provided an update of its business strategy related to its focus on weight management and women's health treatments
Tokai investors are still reeling from the phase III failure over the summer of its lead drug for late-stage prostate cancer.
Allergan, the maker of wrinkle-filler Botox, said on Tuesday that it has agreed to buy regenerative medicine company LifeCell for $2.9bn in cash
Vericel said its MACI product is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee.
Edwards Lifesciences Corp was the top gainer on the S&P 500 on Thursday after being reiterated as a “buy” and management presenting a more bullish earnings outlook for 2017
XBiotech Inc., developer of True Human therapeutic antibodies, on Tuesday announced that enrollment has been completed in its randomized, placebo-controlled Phase I/II study evaluating dosing, safety and efficacy of the company’s novel antibody therapy, 514G3
Bristol-Myers Squibb Company on Tuesday announced updated results for Opdivo monotherapy
Johnson & Johnson shares rose on Friday despite a federal court ruling in Dallas on Thursday which ordered the pharma and its DePuy Orthopaedics unit to pay more than $1bn to six Californian plaintiffs who said they were injured by Pinnacle hip implants
VolitionRx Limited will attend the Citi 2016 Global Healthcare Conference on December 7-8 at The Lotte New York Palace in New York, NY, the company said on Thursday
Zynerba said two of its posters related to its patented synthetic CBD gel will be presented at the annual meeting of the American Epilepsy Society next month
The company has gone cap in hand to investors to fund the international expansion it mentioned last month
Around 75 patients with moderate to severe vulvovaginal candidiasis will be enrolled
PhaseOut is a Phase 2 proof of concept clinical trial of its utrophin modulator ezutromid in patients with DMD.